INTRODUCTION:

Bipolar disorder (BPD) is a chronic psychiatric condition defined by recurrent episodes that significantly interfere with day-to-day functioning and overall well-being. The illness manifests with fluctuating mood states, in which individuals alternate between depressive phases and episodes of elevated mood. In BPD I, mood elevation appears as full-scale mania, often requiring hospitalization.¹

In contrast, patients with BPD II do not experience classic manic episodes but rather cycles of depression interspersed with hypomania, often marked by heightened energy and activity. Cyclothymic disorder has a different presentation. It involves persistent mood instability with recurrent short episodes of hypomania and clusters of depressive symptoms that do not reach the threshold for major depressive disorder (MDD). For diagnosis, these fluctuations must persist for at least two years. Manic episodes usually evolve over days to weeks, though in some cases onset may occur within hours, most often early in the day. Without treatment, both mania and depression may last for weeks to several months. A minority of patients show a continuous, unremitting course. The term rapid cycling refers to occurrence of four or more mood episodes within a year and occurs in roughly 15% of patients, with higher rates in women.

The lifetime prevalence of BPD in the United States is projected at around 1.5%, with onset most commonly between ages 20 and 30, although prodromal features may emerge in adolescence or even late childhood. The overall prevalence is comparable between genders, but women are more likely to present with depressive episodes, while men more frequently experience mania.² Across the illness spectrum, depression is both more common and more disabling than manic or hypomanic episodes. Longitudinal studies reveal that in bipolar I disorder, depressive symptoms occupy nearly one-third of follow-up weeks, compared to less than 10% for mania or hypomania.³ Similarly, bipolar II disorder is dominated by depression rather than hypomania. Depressive phases are the most clinically significant presentation due to their strong association with suicidal thoughts and attempts, profound impairment in social and occupational functioning, and substantial reductions in quality of life.⁴ Despite their importance, existing management alternatives for BPD remain limited and often less effective than those used for mania.⁵

The pharmacological treatment of BPD is particularly challenging. Evidence regarding antidepressant use remains inconsistent; while some patients benefit, overall efficacy is modest.⁶ Moreover, in BPD I, antidepressants can precipitate mania or mania with depression, creating a major safety concern.⁷ This highlights bipolar depression as an area of unmet need, warranting further research into safer and more effective therapies.⁴,⁷ Treatment choices include mood stabilizers, atypical antipsychotics, and antidepressants, but most carry limitations related to tolerability, suboptimal efficacy, or risk of mood disorder.⁸ Depressive episodes in BPD are typically longer than manic or hypomanic ones.⁹ Other studies emphasize that approved medications often have modest response rates and substantial adverse-effect burdens, particularly risks of manic switching.¹⁰ Furthermore, individuals with BPD are at a higher risk for both attempted and completed suicide.¹¹,¹² These challenges underscore the urgent need for therapies that combine efficacy with good tolerability.

Among older treatments, lithium was one of the first effective agents, but its narrow therapeutic window limits use due to frequent adverse drug reactions.¹³ Sodium valproate is widely prescribed. It is especially used for acute mania and as a maintenance therapy, and is considered safe and effective in patients who cannot tolerate lithium.¹⁴ A newer option is lumateperone, an atypical antipsychotic recently approved by the U.S. FDA for both schizophrenia and bipolar depression. It has a characteristic mechanism of action by modulating dopaminergic, glutamatergic and serotonergic pathways, while sparing histaminic, muscarinic, and adrenergic receptors. The drug functions as a presynaptic partial D₂ agonist and postsynaptic antagonist, with therapeutic effects achieved at relatively low receptor occupancy. It also demonstrates potent 5-HT₂A antagonism, modest serotonin reuptake inhibition, and indirect enhancement of NMDA receptor activity through D1 signaling in the prefrontal cortex. These properties improve synaptic connectivity while minimizing risks of extrapyramidal symptoms, sedation, or metabolic complications.⁹,¹⁵,¹⁶

Recent randomized controlled trials support lumateperone’s efficacy in decreasing the depressive symptoms in patients with both BPD I and II, both as monotherapy and as adjunctive treatment. It demonstrates a relatively fast onset of benefit and a favorable tolerability profile, with minimal weight gain or metabolic adverse effects.¹⁷ With these advantages, lumateperone appears to be an important component of management to the therapeutic strategies for BPD.

2. Experimental procedures

2.1 Review Design

This article was designed as a critical narrative review, aiming to synthesize mechanistic, translational, and clinical evidence on lumateperone relevant to bipolar depression. Given the evolving nature of evidence for this agent and the heterogeneity of available studies, a narrative approach was selected to allow integrative interpretation beyond quantitative aggregation.

2.2 Literature Search Strategy

A targeted literature search was performed in PubMed, Scopus, and Embase covering the period January 2000 to June 2025. Search terms included:

· lumateperone, ITI-007

· bipolar depression, bipolar disorder

· major depressive episode

· antipsychotic, second-generation antipsychotic

· dopamine, serotonin, glutamate modulation

2.3 Eligibility criteria

Inclusion criteria:

· Randomised controlled trials (RCTs) involving lumateperone in bipolar disorder or schizophrenia

· Pharmacodynamic and mechanistic studies

· Studies comparing lumateperone with other antipsychotics

· Prescribing information and regulatory data

· Meta-analyses and major psychiatric guidelines

Exclusion criteria:

· Case reports

· Non-English publications

· Preclinical studies not directly relevant to bipolar depression

3. Review of Literature

3.1 Pathophysiology of BPD

BPD is influenced by a complex interplay of biological mechanisms including modification in in dopaminergic, serotonergic, noradrenergic, glutamatergic, and GABAergic circuits.

Monoaminergic dysregulation

· Dopamine: Depressive episodes are associated with reduced dopaminergic transmission, particularly in mesocortical pathways. Post-mortem and imaging studies demonstrate reduced D₂ receptor availability and diminished dopamine turnover.

· Serotonin: Decreased serotonergic signalling contributes to mood dysregulation, suicidality, and anxiety symptoms common in bipolar depression.

· Norepinephrine: Noradrenergic hypoactivity correlates with psychomotor slowing, anergia, and cognitive deficits.¹⁸

Glutamatergic and GABAergic Imbalance

Evidence for aberrant glutamate regulation in BD includes elevated cortical glutamate levels and NMDA receptor dysfunction. These abnormalities contribute to impaired neuroplasticity and cognitive dysfunction. Many novel treatments—including ketamine, rapastinel, and lumateperone—target glutamatergic pathways directly or indirectly.¹⁸

Neuroendocrine and Circadian Dysregulation

Hyperactivity of the HPA axis, neuroinflammation, oxidative stress, and circadian rhythm abnormalities all contribute to depressive relapse and treatment resistance.¹⁸

Genetic factors

Genetic predisposition plays a key role in the pathogenesis of BPD. Evidence from family and twin studies strongly supports heritability, with monozygotic twin concordance rates reported as high as 80%.¹⁹ Advances in genome-wide association studies (GWAS) have revealed multiple susceptibility loci, many of which are also implicated in other psychiatric conditions such as autism and schizophrenia, highlighting overlapping biological pathways.²⁰

CACNA1C: Codes for the α-subunit of the L-type calcium channel, essential for neurotransmitter release and neuronal excitability. Variants in this gene are strongly linked to BD and other psychiatric illnesses.²¹
ANK3: Encodes ankyrin-G, which regulates clustering of voltage-gated sodium channels at the axon initial segment. Genetic alterations have been linked with both BPD and schizophrenia.²¹
ODZ4: Produces teneurin transmembrane protein 4, a molecule critical for neuronal development and synaptic organization. GWAS have consistently identified ODZ4 as a risk locus in BD.²²
NCAN: Encodes neurocan, an extracellular matrix glycoprotein, which lies within the central nervous system (CNS). Variants in NCAN have been correlated with BD as well as other psychiatric conditions.²²
TRANK1: Encodes tetratricopeptide repeat and ankyrin repeat containing 1, a signaling-related protein. GWAS studies have highlighted TRANK1 as a susceptibility gene for BPD.²²

Overall, bipolar depression results from multifactorial disturbances, creating opportunities for multimodal treatments such as lumateperone.

3.2 Neuropsychopharmacological Mechanisms of Lumateperone

Lumateperone exhibits a multimodal pharmacological profile that distinguishes it from conventional second-generation antipsychotics and aligns with contemporary neurobiological models of bipolar depression emphasizing circuit-level dysregulation and impaired synaptic plasticity.¹⁶,²³,²⁴

3.2.1 Dopaminergic Actions

In contrast to drugs that primarily block postsynaptic dopamine D₂ receptors, lumateperone modulates dopamine in a context-dependent manner by two different mechanisms:

· Presynaptic partial D₂ agonism, enhancing autoreceptor-mediated regulation of dopamine release.^16,23

· Postsynaptic D₂ antagonism, reducing hyperdopaminergic states implicated in mania¹⁶

Importantly, therapeutic effects are achieved at relatively low striatal D₂ receptor occupancy (~40%), a feature associated with a markedly reduced risk of extrapyramidal symptoms and prolactin elevation.²³,²⁴ This balanced dopaminergic modulation may stabilize mesocortical dopamine transmission, which is frequently diminished during bipolar depressive episodes.³,⁹

3.2.2 Serotonergic Actions

Lumateperone also acts on key serotonergic pathways relevant to mood, anxiety, and sleep regulation.

· Potent 5-HT₂A receptor antagonism, producing antidepressant and anxiolytic effects and contributing to sleep regulation.¹⁶,²³,²⁴

· Modest serotonin reuptake inhibition (SERT inhibition), enhancing serotonergic tone.¹⁶

· Minimal affinity for 5-HT₂C receptors, supporting its favourable metabolic profile.²³,²⁴

The strong 5-HT₂A antagonism combined with mild SERT inhibition contributes to its antidepressant efficacy in bipolar depression.¹⁶

3.2.3 Glutamatergic and NMDA-related Modulation

A defining neuropsychopharmacological feature of lumateperone is its indirect enhancement of NMDA receptor signaling, mediated through dopamine D₁ receptor–dependent glutamatergic pathways in the prefrontal cortex.¹⁶,²³ This mechanism contrasts with direct NMDA antagonists such as ketamine and is associated with:

· Improved synaptic plasticity¹⁶

· Restoration of excitatory–inhibitory balance¹⁸

· Potential cognitive and affective benefits¹⁶^,¹⁸

Given accumulating evidence implicating glutamatergic dysfunction and impaired neuroplasticity in bipolar depression, lumateperone’s mechanism aligns with emerging treatment paradigms that target downstream synaptic processes rather than monoaminergic systems alone.¹⁸

3.2.4 Histaminic, Muscarinic, and Adrenergic Sparing

Lumateperone exhibits minimal affinity for histaminic H₁, muscarinic, and α₁-adrenergic receptors, which likely accounts for its low propensity for sedation, anticholinergic effects, orthostatic hypotension, and metabolic dysregulation.²³^,²⁴ This receptor-sparing profile supports its clinical tolerability and may facilitate long-term use in populations vulnerable to cardiometabolic adverse effects.⁵^,⁸

3.2.5 Integrated Mechanistic Perspective

Collectively, lumateperone’s pharmacology supports an integrated neuropsychopharmacological model in which coordinated modulation of dopaminergic, serotonergic, and glutamatergic systems contributes to symptom improvement in bipolar depression. Rather than producing broad neurotransmitter blockade, lumateperone appears to restore functional balance across cortical–limbic circuits implicated in mood regulation.¹⁶^,²³^,²⁴

3.3 Circuit-Level and Translational Neuropsychopharmacological Framework

Bipolar depression is increasingly conceptualized as a disorder of distributed neural circuits rather than isolated neurotransmitter deficits. Dysregulation within prefrontal–striatal–limbic networks, involving aberrant dopaminergic, serotonergic, and glutamatergic signaling, contributes to impaired mood regulation, reward processing, cognitive control, and emotional reactivity.³,⁹,¹⁸ Contemporary neuropsychopharmacology therefore emphasizes treatments capable of restoring circuit-level balance and synaptic plasticity, rather than producing broad neurotransmitter blockade.

3.3.1 Prefrontal–Striatal Dopaminergic Stabilization

During bipolar depressive episodes, reduced dopaminergic tone in mesocortical pathways is associated with anhedonia, cognitive slowing, and impaired executive function.³,⁹ In contrast, excessive dopaminergic signaling in subcortical regions has been implicated in mood instability and manic switching.⁶,⁷ Lumateperone’s dual dopaminergic action—presynaptic D₂ partial agonism combined with postsynaptic D₂ antagonism—may promote stabilization across these circuits by attenuating subcortical hyperdopaminergia while preserving cortical dopamine signaling.¹⁶,²³ This contrasts with conventional antipsychotics that rely on high D₂ occupancy and may exacerbate motivational and cognitive deficits through excessive dopamine blockade.²³,²⁴

3.3.2 Cortical Disinhibition via 5-HT₂A Antagonism

The prefrontal cortex plays a central role in top-down emotional regulation, and impaired cortical inhibitory control has been consistently implicated in bipolar depression.¹⁸ Potent antagonism of cortical 5-HT₂A receptors, as seen with lumateperone, is thought to reduce excessive glutamatergic noise and improve signal integration within prefrontal networks.¹⁶,²³ In addition to its effects on mood and anxiety symptoms, 5-HT₂A antagonism may contribute to improved sleep architecture and emotional regulation—domains frequently disrupted in bipolar disorder.⁵,⁹ Unlike agents with significant histaminic or anticholinergic activity, lumateperone achieves these effects without prominent sedation or cognitive impairment.²³,²⁴

3.3.3 Glutamatergic Modulation and Synaptic Plasticity

Mounting evidence implicates glutamatergic dysfunction and impaired NMDA receptor signalling in the pathophysiology of bipolar depression, contributing to deficits in synaptic plasticity and neurocognitive functioning.¹⁸ Direct NMDA antagonists such as ketamine produce rapid antidepressant effects but are limited by dissociative symptoms and abuse potential. Lumateperone indirectly enhances NMDA receptor–mediated neurotransmission via dopamine D₁ receptor–dependent signalling in the prefrontal cortex, offering a mechanistically distinct approach to modulating glutamatergic function.¹⁶ This indirect modulation may support restoration of synaptic connectivity and plasticity while avoiding the adverse effects associated with direct NMDA antagonism.¹⁶,¹⁸

3.3.4 Integrated Neuropsychopharmacological Model

Taken together, lumateperone’s pharmacological actions suggest an integrated neuropsychopharmacological model in which coordinated modulation of dopaminergic, serotonergic, and glutamatergic systems converges on cortical–limbic circuits implicated in bipolar depression. Rather than acting as a broad-spectrum antagonist, lumateperone appears to function as a circuit stabilizer, restoring functional balance across interconnected neural networks that govern mood, cognition, and emotional regulation.¹⁶,²³,²⁴ This multimodal mechanism aligns with emerging perspectives in neuropsychopharmacology that prioritize network-level modulation and synaptic resilience as key therapeutic targets in mood disorders.¹⁸

Pharmacokinetic profile

Lumateperone is administered orally and demonstrates pharmacokinetic properties supportive of once-daily dosing and central nervous system penetration. Following oral administration, peak plasma concentrations are achieved within approximately 1–2 hours, and the terminal elimination half-life is around 18 hours, consistent with sustained receptor engagement over a 24-hour dosing interval.¹⁶,^17,²³, Lumateperone is highly protein bound (~97%) and exhibits a large volume of distribution, suggesting extensive tissue distribution, including the central nervous system.²³ The drug undergoes predominantly hepatic metabolism, primarily via CYP3A4, with minor contributions from CYP1A2 and CYP2C8 pathways.¹⁶,17 Elimination occurs mainly through fecal excretion, with a smaller proportion excreted renally. Food intake does not produce clinically meaningful effects on drug exposure.¹⁶ Based on available data, dose adjustment is not required in patients with mild to moderate hepatic or renal impairment.¹⁶

4. Evidence from Clinical Trials

4.1 Monotherapy Trials in Bipolar Depression

The pivotal Phase 3 randomised controlled trial by Calabrese et al. (2021) demonstrated that lumateperone 42 mg daily produced significantly greater reductions in Montgomery–Åsberg Depression Rating Scale (MADRS) scores compared with placebo in patients with bipolar I or II depression.¹⁶

Key findings included

· Symptom improvement detectable by Week 1,

· An effect size comparable to or greater than several approved atypical antipsychotics, and

· A low incidence of mania or hypomania induction, consistent with broader evidence on switching risks in bipolar disorder.⁷

The observed efficacy was complemented by notable improvements in anxiety-related symptoms and functional outcomes.¹⁶

4.2 Adjunctive Therapy Trials

The adjunctive trial in which lumateperone was added to lithium or valproate reported clinically meaningful reductions in depressive symptoms compared with adjunctive placebo.¹⁸

Patients exhibited:

· Low discontinuation rates,

· Minimal sedation,

· Negligible metabolic change.

These findings are clinically significant given concerns about metabolic adverse effects seen with agents such as quetiapine and olanzapine–fluoxetine combination (OFC).⁵^,⁸

4.3 Supportive Evidence from Schizophrenia Trials

Although conducted in schizophrenia, efficacy and tolerability data from lumateperone’s Phase 3 trials strengthen the understanding of its safety profile.²³

Across these studies:

· Weight gain was minimal

· Extrapyramidal symptoms (EPS) were rare, and

· QT prolongation was not clinically significant.^17,²³^,

Given that many antipsychotics used in bipolar depression (e.g., quetiapine, OFC) carry considerable metabolic or cardiovascular risk, these findings are relevant for clinical decision-making.⁵^,⁸

5. Comparative Analysis with Other Bipolar Depression Treatments

5.1 Quetiapine

Quetiapine’s efficacy in bipolar depression is well established, but its utility is limited by prominent sedation, weight gain, and metabolic abnormalities.⁵,⁸
In contrast, lumateperone demonstrates comparable antidepressant efficacy without significant metabolic changes or sedation.¹⁶,^17,²³,

5.2 Lurasidone

Lurasidone is effective and generally weight-neutral but is associated with higher rates of akathisia and nausea, and requires ingestion with food to ensure adequate absorption.⁵,⁸,⁹
Lumateperone offers similar efficacy for depressive symptoms with substantially lower rates of EPS and gastrointestinal adverse effects.¹⁶,²³

5.3 Cariprazine

Cariprazine demonstrates good efficacy in bipolar depression, particularly in anergic or apathetic patients, but can cause activation and akathisia.⁵
Lumateperone, with its low D₂ occupancy and receptor-sparing activity, provides a more tolerable profile for patients sensitive to EPS.¹⁶,^17,²³,

5.4 Olanzapine–Fluoxetine Combination (OFC)

The OFC regimen is effective, especially in severe bipolar depression, but has the highest risk of weight gain and metabolic syndrome among approved treatments.⁵,¹¹
Lumateperone’s minimal metabolic impact and low sedation make it a safer alternative for long-term management.^17,²³

5.5 Contextualising Lumateperone Within Treatment Guidelines

Recent guidelines and reviews highlight the challenges in managing bipolar depression, including modest antidepressant efficacy, risk of mania induction, and metabolic complications. Within this landscape, lumateperone’s mechanism and safety profile align with current calls for treatments that balance efficacy with tolerability.¹⁶,^17,²

6. Safety and Tolerability

Clinical data indicate that lumateperone is usually well tolerated and offers a more favorable safety profile compared with many other antipsychotics. The frequently reported ADRs include sedation, dry mouth, dizziness and nausea, which are typically mild, transient, and self-limiting. Due to its relatively low dopamine D₂ receptor occupancy, the frequency of extrapyramidal symptoms (EPS) is minimal. In addition, lumateperone has a beneficial metabolic profile, showing negligible effects on body weight, glucose regulation, lipid levels, and prolactin, distinguishing it from many atypical antipsychotics. Serious adverse reactions are rare, and available evidence suggests a low risk of QT interval prolongation, with no clinically meaningful cardiac safety issues observed in trials.^17,²³ This overall tolerability supports long-term treatment, especially in patients vulnerable to metabolic complications or those particularly sensitive to antipsychotic-related adverse events. Detailed adverse reactions are presented in Table 1.¹⁷

ADR	Incidence (%)	Severity
Somnolence/Sedation	~24%	Mild to moderate
Dizziness	~8%	Mild
Dry Mouth	~6%	Mild
Nausea	~6%	Mild to moderate
Extrapyramidal Symptoms	≤2%	Mild
Weight gain	Minimal (~<1 kg on average)	Low clinical significance
Akathisia	<2%	Mild
Increased prolactin	Not significant	None
QT prolongation	No significant changes observed	Not clinically relevant

Table 1- Detailed ADR’s encountered in Clinical Trials with Lumateperone

7. Dosage, administration and drug interactions

The recommended dose of lumateperone for both indications is 42 mg, orally once daily with or without food and no titration is required at treatment initiation. The summary of Potential Drug Interactions with Lumateperone is described in Table 2.¹⁶

Interacting Agent/Class	Interaction Type	Clinical Impact	Recommendation
Strong CYP3A4 inhibitors	Inhibition of metabolism	↑ Lumateperone levels → ↑ risk of side effects	Avoid co-administration
Strong CYP3A4 inducers	Increased metabolism	↓ Lumateperone levels → ↓ efficacy	Avoid co-administration
CNS depressants	Additive CNS depression	↑ Risk of sedation, dizziness	Monitor closely or avoid combinations
Serotonergic drugs (SSRIs, SNRIs)	Serotonin syndrome	Theoretical risk of serotonin toxicity	Monitor; low risk in practice
QT-prolonging agents	Additive QT prolongation	Potential cardiac risk	Use with caution and monitor ECG

Table 2- Summary of Potential Drug Interactions with Lumateperone

Clinicians need to be aware of Co-administration of lumateperone with CNS depressants, such as alcohol or benzodiazepines as it may lead to additive sedative effects and impaired psychomotor performance. Although lumateperone has a low risk of QT prolongation, caution is advised when used with other QT-prolonging agents. All medication regimens need to be assessed thoroughly to ensure safe.

8. Place of Lumateperone in Therapy

Based on current evidence, lumateperone is particularly useful for:

· Patients intolerant of sedation (vs quetiapine)

· Patients at risk for metabolic disease (vs quetiapine, OFC)

· Those sensitive to akathisia (vs cariprazine, lurasidone)

· Patients requiring once-daily dosing

· Individuals with anxiety and sleep disturbance (via 5-HT₂A antagonism)

· Bipolar II patients, who often experience prolonged depressive episodes

Its tolerability profile strongly supports earlier use in treatment algorithms.

9. Limitations

While lumateperone demonstrates efficacy and a favorable tolerability profile in bipolar depression, current evidence is primarily derived from short-term randomized controlled trials. Long-term safety data remain limited, particularly regarding rare adverse events and sustained metabolic effects. Additionally, most studies have excluded patients with significant medical comorbidities, limiting generalizability to real-world populations.

10. Future Directions

Further research should focus on large-scale, continuing studies to establish robustness of response, relapse prevention and comparative effectiveness against established agents. Exploring lumateperone’s role in treatment-resistant bipolar depression, rapid cycling, and comorbid conditions may expand its clinical utility. Biomarker-based studies could also help identify patient subgroups most likely to benefit from treatment.

CONCLUSION:

Lumateperone represents a promising therapeutic option for bipolar depression, offering efficacy with a favorable safety and tolerability profile compared to many existing antipsychotics. While current evidence is encouraging, continued research is essential to fully establish its long-term clinical value and optimize its integration into treatment guidelines.

REFERENCES:

1. Goes FS. Diagnosis and management of bipolar disorders. BMJ 2023;381:e073591.

2. Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of Internal Medicine. 21st ed. New York: McGraw Hill; 2022. Chapter “Psychiatric Disorders: Bipolar Disorder,” pp. 2690-8.

3. Judd LL, Schettler PJ, Akiskal HS, Coryell W, Fawcett J, Fiedorowicz JG, Solomon DA. Depressive symptoms predominate in long-term course of bipolar I disorder. JAMA Psychiat. 2002;59(4):341–9

4. Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, Hopwood M, Lyndon B, Mulder R, Porter R, Singh AB, Murray G. The nature and management of depression in bipolar disorder: A narrative review. Lancet Reg Health Eur. 2024;38:100678.

5. Pacchiarotti I, Anmella G, Verdolini N, Samalin L, Carvalho AF, Vieta E. Mood stabilizers and antipsychotics for bipolar depression: an updated overview. Front Psychiatry. 2022;13:932789.

6. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW et.al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249–62.

7. De Giorgi R, Zamboni L, Martino M, Vita A, Serafini G, Girardi P, et.al. Antidepressant-induced mood switching in patients with bipolar disorder: A systematic review and meta-analysis. Lancet Psychiatry. 2025;12(3):215–28.

8. Kim HK, Banik S, Husain MI, Tang V, Levitan R, Daskalakis ZJ, Kloiber S. Systematic review of structured care pathways in major depressive disorder and bipolar disorder. BMC psychiatry. 2023;23(1):85.

9. Nierenberg AA, Agustini B, Köhler-Forsberg O, Cusin C, Katz D, Sylvia LG et.al. Diagnosis and treatment of bipolar disorder: a review. JAMA. 2023;330(14):1370-80.

10. Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9(5):531–5.

11. Cheniaux E, Nardi AE. Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder. Expert Opin Drug Saf. 2019;18(10):893-913.

12. Fiedorowicz JG, Leon AC, Keller MB, Solomon DA, Rice JP, Coryell WH. Do risk factors for suicidal behavior differ by affective disorder polarity? Psychol Med. 2009;39(5):763-71.

13. Joseph G, Badyal DK, Gulrez G, Renji M. A rare case of lithium-induced quadriparesis in a patient with bipolar disorder. J Rational Pharmacother Res. 2018;4(1):48-50.

14. Abhilasha P, Bhatti N, Joseph G, Badyal DK. Sodium Valproate-Induced Hyperammonemia: A Case Series in a Tertiary Care Hospital. Cureus. 2024;16(7).

15. De Crescenzo F, Serra G, Maisto F, Uchida M, Woodworth H, Casini MP, Baldessarini RJ, Vicari S. Suicide attempts in juvenile bipolar versus major depressive disorders: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2017;56(10):825-31.

16. Calabrese JR, Durgam S, Satlin A, Vanover KE, Davis RE, Chen R, et.al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. 2021;178(12):1098-106.

17. U.S. Food and Drug Administration. CAPLYTA (lumateperone) prescribing information. Silver Spring (MD): FDA; 2021 [cited 2025 Jun 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209500s003lbl.pdf

18. Suppes T, Durgam S, Kozauer SG, Chen R, Lakkis HD, Davis RE, et.al. Adjunctive lumateperone (ITI‐007) in the treatment of bipolar depression: results from a randomized placebo‐controlled clinical trial. Bipolar Disord. 2023;25(6):478-88.

19. Kieseppä T, Partonen T, Haukka J, Kaprio J, Lönnqvist J. High concordance of bipolar I disorder in a nationwide sample of twins. Am J Psychiatry. 2004;161(10):1814-21.

20. Mühleisen TW, Leber M, Schulze TG, Strohmaier J, Degenhardt F, Treutlein J et al. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun. 2014;5:3339.

21. Li HJ, Zhang C, Hui L, Zhou DS, Li Y, Zhang CY, et.al. Novel risk loci associated with genetic risk for bipolar disorder. JAMA Psychiatry. 2021;78(3):320-30.

22. Fiorentino A, O'Brien NL, Locke DP, McQuillin A, Jarram A, Anjorin A et.al. Analysis of ANK3 and CACNA1C variants identified in bipolar disorder whole genome sequence data. Bipolar Disord. 2014 Sep;16(6):583-91.

23. Correll CU, Davis RE, Weingart M, Saillard J, O’Gorman C, Kane JM et.al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA psychiatry. 2020;77(4):349-58.

Lumateperone in Bipolar Depression: A Critical Review of Pharmacology, Clinical Evidence, and Therapeutic Positioning

Article Information:

Abstract:

Keywords:

Article :